Stuart L. Goldstein, MD, FAAP, FNKF

Clark D. West Endowed Chair

Director, Center for Acute Care Nephrology 

Medical Director, Pheresis Service

Co-Medical Director, Heart Institute Research Core

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-2078

Fax 513-636-7407

Email stuart.goldstein@cchmc.org

Clinical

Acute kidney injury; continuous renal replacement therapy; cardio-renal syndrome; nephrotoxic medication associated morbidity

Research

Acute kidney injury epidemiology and biomarkers; heart failure associated chronic kidney disease; nephrotoxic medication associated acute kidney injury reduction

Stuart L. Goldstein, MD, has been an active investigator in the field of pediatric acute kidney injury (AKI) since 2000. Dr. Goldstein’s main research foci include: AKI epidemiology and outcomes, acute renal replacement therapy provision and investigation of novel urinary AKI biomarkers in the pediatric population. Dr. Goldstein has established a strong record of interdisciplinary and inter-institutional collaboration with cardiologists, intensivists and emergency center physicians, which is evidenced by his establishment and directing of the Prospective Pediatric Continuous Renal Replacement Therapy Registry from 2001 to 2012, and the Prospective Pediatric AKI Research Group (ppAKI-RG) in 2012. The ppAKI-RG is comprised of 52 centers from around the world with the goal of improving outcomes for the child with or at-risk for, AKI.

Dr. Goldstein has led efforts to develop a standardized definition for pediatric AKI, assess novel AKI biomarkers in heterogeneous populations, and conceiving and validating stratification tools to identify patients at risk for AKI. Building upon these findings, Dr. Goldstein embarked on establishing the ppAKI-RG consortium to focus on multi-centered research studies that are dedicated to understanding and treating AKI in pediatric patients. Currently, the ppAKI-RG has completed three major, and unprecedented, national and international studies (AWARE, NINJA and DIRECT) to accurately characterize pediatric AKI epidemiology, reduce AKI and improve patient outcomes. Dr. Goldstein is also a recognized educator; he and his team host the CRRT University™ course, which provides an high-fidelity simulation experience to pediatric and adult CRRT programs from around the country with a faculty of world renowned experts in AKI. In addition he has developed the only pediatric specific acute care nephrology sub-specialty fellowship with graduates who are now leaders in the field of pediatric AKI.

MD: Columbia College of Physicians and Surgeons, New York, NY, 1990.

Residency: Baylor College of Medicine, Houston, TX.

Fellowship: Pediatric Nephrology, Children's Hospital, Boston, MA.

Clinical Evaluation of the Prismaflex™ HF20 Set and Prismaflex™Control Unit Version 5.10 Software for Acute Continuous Renal Replacement Therapy (CRRT) in Children. Principal Investigator. Gambro Renal Products, Inc. Mar 2014–Mar 2018.

Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care. Principal Investigator. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Trials Network-POPS. Feb 2013–Feb 2018.

Recombinant Erythropoietin Protects Against Kidney Disease. Principal Investigator. National Institutes of Health. Sep 2014–Aug 2019.

Reduction of Nephrotoxic Medication Associated Acute Kidney Injury in Children: Dissemination of a Successful Quality Improvement Project. Principal Investigator. Agency for Healthcare Research and Quality. Apr 2015–Mar 2018.